Floatz logo

PCK-HGFX7

Amyotrophic Lateral Sclerosis

Helixmith Co., Ltd.gene_therapyPhase 1/2Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
73/ 100

Competitive context

151 Active assets in the Amyotrophic Lateral Sclerosis cohort.

Asset / SponsorPhaseRating
TAURURSODIOL
Amylyx Pharmaceuticals Inc.
Phase 3BBB
Tofersen
Biogen
Phase 4BBB
Mexiletine
Bjorn Oskarsson, MD
Phase 4BB
Riluzole
AB Science
Phase 4BB
DIACETYL(N(4)-METHYLTHIOSEMICARBAZONATO) COPPER (II)
Collaborative Medicinal Development Pty Limited
Phase 2/3BB

View all 50 →

Same molecule, other indications

PCK-HGFX7 is also rated in:

Critical Limb IschemiaDormant
B
Indicative ·
57 / 100
View asset →
Painful Diabetic NeuropathiesDormant
B
Indicative ·
57 / 100
View asset →
myocardial ischemiaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →